J. Nagashima et al. / Phytochemistry 71 (2010) 1564–1572
1571
(2H, dd, J = 12, 5 Hz, H-6000b and 600000b), 3.38–3.25 (6H, m, H-3000, 4000,
5000, 300000, 400000 and 500000), 3.26 (2H, dd, J = 9, 8 Hz, H-2000and 200000), 2.35
(2H, m, H-600a and 60000a), 1.83 (1H, m, H-400), 1.94–1.82 (2H, m,
H-300a and 30000a), 1.67 (1H, m, H-40000), 1.51 (1H, m, H-50000b), 1.37–
1.22 (6H, m, H-300b, 500a, 600b, 30000b, 50000a and 60000b), 1.10 (1H, m,
H-500b); for 13C NMR (CD3OD, 150 MHz) spectroscopic data, see
and 50), 3.16 (1H, dd, J = 8, 8 Hz, H-20), 1.93 (1H, ddd, J = 15, 7,
7 Hz, H-8a), 1.83 (1H, ddd, J = 15, 7, 7 Hz, H-8b), 1.82 (1H, m, H-
3a), 1.72 (1H, m, H-6a), 1.52 (1H, m, H-4), 1.23–1.26 (1H, m, H-
5a), 1.26 (1H, m, H-6b), 1.18 (1H, m, H-3b), 1.12 (1H, dddd, J = 13,
13, 13, 3 Hz, H-5b); HRESIMS (positive-ion mode) m/z: 389.1787
[M+Na]+ (Calcd. for C16H30O9Na: 389.1782).
Table 2; CD
D
e
(nm) ꢁ0.07 (361), +12.6 (309), +7.33 (257), ꢁ29.8
(229) (c 5.49 ꢂ 10ꢁ5 m, MeOH); HRESIMS (positive-ion mode) m/
4.12.4. Enzymatic hydrolysis of deacyldihydrocanangafruticoside A
7-ol (5c)
z: 1053.3579 [M+Na]+ (Calcd. for C50H62O23Na: 1053.3574).
Dihydrocanangafruticoside A 7-ol (5c) (2.2 mg) was dissolved in
20 mM acetate buffer (1.2 mL) and then hesperidinase (1 mg) was
added. The mixture was incubated for 18 h at 37 °C. The aglycone
(5d) (0.9 mg) and glucose were purified by prep. TLC (CHCl3–
MeOH–H2O, 15:6:1). Aglycone (5d): colorless oil; 1H NMR (CD3OD,
400 MHz) d: 3.84 (1H, d, J = 11 Hz, H-7a), 3.76 (1H, ddd, J = 11, 8,
6 Hz, H-9a), 3.69 (1H, ddd, J = 11, 6, 5 Hz, H-9b), 3.64 (1H, d,
J = 11 Hz, H-7b), 3.52 (1H, dd, J = 12, 5 Hz, H-2), 3.42 (1H, dd,
J = 11, 6 Hz, H-10a), 3.41 (1H, dd, J = 11, 6 Hz, H-10b), 1.85–1.78
(3H, m, H-6a, 8a and 8b), 1.69 (1H, ddd, J = 15, 5, 5 Hz, H-3a),
1.53 (1H, m, H-4), 1.32–1.22 (2H, m, H-5a and 6b), 1.15–1.07
(2H, m, H-3b and 5b); HRESIMS (positive-ion mode) m/z:
227.1257 [M+Na]+ (Calcd. for C10H20O4Na: 227.1253). Glucose
was analyzed with a chiral detector (JASCO OR-2090plus) on an
amino column [Asahipak NH2P-50 4E, CH3CN–H2O (4:1), 1 mL/
min], a peak at 14.5 min with a positive optical rotation sign being
observed. Peak was identified by co-chromatography with authen-
4.12. Modified Mosher0s method for canangafruticoside E (5)
4.12.1. Catalytic hydrogenation of canangafruticoside E (5)
Canangafruticoside E (5) (10.0 mg) was dissolved in 1 mL of
MeOH and then reduced with PtO2 (1 mg) under a H2 atmosphere
for 1 h. The catalyst was removed by filtration and the filtrate was
evaporated to dryness to give tetrahydrocanangafruticoside E (5a)
(10.1 mg). Tetrahydrocanangafruticoside E (5a): amorphous pow-
der; 1H NMR (CD3OD, 400 MHz) d: 9.82 (1H, s, H-7), 6.66 (1H, dd,
J = 8, 2 Hz, H-500), 6.61 (1H, d, J = 2 Hz, H-200), 6.50 (1H, d, J = 8 Hz,
H-600), 4.22 (1H, d, J = 8 Hz, H-10), 4.02 (1H, dd, J = 10, 6 Hz, H-
10a), 4.01 (1H, dd, J = 10, 6 Hz, H-10b), 4.00 (1H, ddd, J = 11, 6,
6 Hz, H-9a), 3.86 (1H, m, H-60a), 3.68 (1H, m, H-2), 3.66 (1H, m,
H-60b), 3.60 (1H, m, H-9b), 3.33 (1H, m, H-30), 3.33–3.25 (1H, m,
H-40), 3.25 (1H, m, H-50), 3.13 (1H, dd, J = 9, 8 Hz, H-20), 2.76 (2H,
t, J = 7 Hz, H2-700), 2.55 (2H, t, J = 7 Hz, H2-800), 2.26 (1H, ddd,
J = 14, 7, 6 Hz, H-8a), 2.07 (1H, ddd, J = 14, 3, 3 Hz, H-6a), 1.86
(1H, m, H-3a), 1.81 (2H, m, H-4 and 8b), 1.54 (1H, m, H-5a), 1.22
(2H, m, H-5b and 6b), 1.16 (1H, m, H-3b); HRESIMS (positive-ion
mode) m/z: 551.2091 [M+Na]+ (Calcd. for C25H36O12Na: 551.2098).
tic D-glucose.
4.12.5. Protection of the primary alcohols of aglycone (5d)
The aglycone (5d) (0.9 mg) was dissolved in pyridine (1 mL) and
pivaloyl chloride (8 lL) was added. The reaction mixture was stir-
4.12.2. NaBH4 reduction of tetrahydrocanangafruticoside E (5a)
Tetrahydrocanangafruticoside E (5a) (10.1 mg) was dissolved in
EtOH (1 mL) and then cooled on an ice-bath. NaBH4 (1 mg) in EtOH
red for 3 h at 25 °C. To the reaction mixture, H2O (1 mL) was added,
followed by extracted with EtOAc (2 mL ꢂ 3). The residue from the
dried (Na2SO4) organic layer was purified by prep. TLC [CHCl3–
(CH3)2CO, 20:1] to give tripivalate (1.2 mg) (5e). Tripivalate (5e):
colorless oil; 1H NMR (CDCl3, 400 MHz) d: 4.28 (1H, d, J = 12 Hz,
H-7a), 4.22 (2H, t, J = 7 Hz, H2–9), 4.18 (1H, d, J = 12 Hz, H-7b),
3.94 (1H, dd, J = 11, 6 Hz, H-10a), 3.91 (1H, dd, J = 11, 6 Hz, H-
10b), 3.60 (1H, dd, J = 12, 5 Hz, H-2), 1.90 (1H, ddd, J = 14, 7, 7 Hz,
H-8a), 1.85 (1H, m, H-3a), 1.84 (1H, ddd, J = 14, 7, 7 Hz, H-8b),
1.78 (1H, m, H-4), 1.76 (1H, m, H-6a), 1.35 (1H, m, H-3b), 1.35–
1.10 (2H, m, H2-5), 1.21 (1H, m, H-6b), 1.180, 1.184, 1.20 (each
9H, each s, CH3 ꢂ 3); HRESIMS (positive-ion mode) m/z: 479.2984
[M+Na]+ (Calcd. for C25H44O7Na: 479.2979).
(500
l
L) was added, followed by stirring for 30 min. Excess NaBH4
L of a 1% EtOH solution of
was quenched by the addition of 500
l
acetic AcOH. The reduced product was purified by prep. TLC
(CHCl3–MeOH–H2O, 15:6:1) to give tetrahydrocanangafruticoside
E 7-ol (5.6 mg) (5b). Tetrahydrocanangafruticoside E 7-ol (5b):
amorphous powder; 1H NMR (CD3OD, 400 MHz) d: 6.66 (1H, d,
J = 8 Hz, H-500), 6.62 (1H, d, J = 2 Hz, H-200), 6.51 (1H, dd, J = 8,
2 Hz, H-600), 4.29 (1H, d, J = 8 Hz. H-10), 4.10 (1H, ddd, J = 10, 7, 7,
Hz, H-9a), 3.92 (2H, d, J = 6 Hz, H2-10), 3.86 (1H, dd, J = 12, 1 Hz,
H-60a), 3.84 (1H, d, J = 11 Hz, H-7a), 3.76 (1H, ddd, J = 10, 7, 7 Hz,
H-9b), 3.66 (1H, m, H-60b), 3.60 (2H, m, H-2 and 7b), 3.35 (1H, m,
H-30), 3.33–3.25 (2H, m, H-40 and 50), 3.17 (1H, dd, J = 9, 8 Hz, H-
20), 2.77 (2H, t, J = 7 Hz, H2-700), 2.56 (2H, t, J = 7 Hz, H2-800), 1.92
(1H, m, H-8a), 1.83 (1H, ddd, J = 15, 7, 7 Hz, H-8b), 1.72 (1H, m,
H-6a), 1.71 (1H, ddd, J = 13, 3, 3 Hz, H-3a), 1.65 (1H, m, H-4), 1.37
(1H, m, H-5a), 1.31 (1H, m, H-6b), 1.16 (1H, m, H-3b), 1.11 (1H,
m, 5b); HRESIMS (positive-ion mode) m/z: 553.2258 [M+Na]+
(Calcd. for C25H38O12Na: 551.2255).
4.12.6. Preparation of (R)- and (S)-MTPA esters (5f and 5g) of
tripivalate (5e)
A solution of 5e (0.6 mg) in dry CH2Cl2 (1 mL) was reacted with
(R)-MTPA (50 mg) in the presence of EDC (40 mg) and 4-DMAP
(25 mg), and then the mixture was occasionally stirred at 25 °C
for 30 min and then at 40 °C for 5 min. After the addition of CH2Cl2
(1 mL), the solution was washed with H2O (1 mL), 4 N HCl (1 mL),
NaHCO3-saturated H2O, and then brine (1 mL), successively. The
organic layer was dried (Na2SO4) and then evaporated under re-
duced pressure. The residue was purified by prep. TLC [silica gel
(0.25 mm thickness), being applied for 18 cm, with development
with CHCl3–(CH3)2CO (19:1) for 9 cm and then elution with
CHCl3–MeOH (9:1)] to furnish an MTPA ester, 5f (0.5 mg). Through
a similar procedure, the (S)-MTPA ester (5g) of tripivalate (0.6 mg)
was prepared from 5e (0.6 mg) using (S)-MTPA (44 mg), EDC
(31 mg), and 4-DMAP (21 mg).
4.12.3. Removal of acyl group from tetrahydrocanangafruticoside E
7-ol (5b)
Tetrahydrocanangafruticoside E 7-ol (5b) (5.6 mg) was dis-
solved in methanolic solution of 0.1 M NaOCH3 (1 mL), followed
by stirring for 30 min at 25 °C. The reaction solvent was neutral-
ized with Amberlite IR-120B (H+) and dihydrocanangafruticoside
A 7-ol (5c) (2.2 mg) was purified by prep. TLC (CHCl3–MeOH–
H2O, 15:6:1). Dihydrocanangafruticoside A 7-ol (5c): amorphous
1
powder; H NMR (CD3OD, 400 MHz) d: 4.29 (1H, d, J = 8 Hz, H-10),
(R)-MTPA ester (5f): 1H NMR (CDCl3, 400 MHz) d: 7.43 (2H, m,
aromatic protons), 7.33–7.31 (3H, m, aromatic protons), 4.98 (1H,
dd, J = 11, 5 Hz, H-2), 4.43 (1H, J = 12 Hz, H-7a), 3.98 (2H, m, H2-
9), 3.87 (2H, m, H2-10), 3.68 (1H, d, J = 12 Hz, H-7b), 3.47 (3H, s,
–OCH3), 2.00 (1H, m, H-3a), 1.89 (1H, m H-6a), 1.83 (1H, m, H-4),
4.11 (1H, ddd, J = 10, 7, 7 Hz, H-9a), 3.87 (2H, br d, J = 12 Hz, H-7a
and 60a), 3.77 (1H, ddd, J = 10, 7, 7 Hz, H-9b), 3.66 (1H, dd, J = 12,
4 Hz, H-60b), 3.63 (1H, d, J = 12 Hz, H-7b), 3.62 (1H, m, H-2), 3.41
(2H, d, J = 6 Hz, H2-10), 3.34 (1H, m, H-30), 3.32–3.25 (2H, m, H-40